Transaktionen anzeigen
Gesundheitswesen

Trigon Holding, Inc. has sold all the assets of StelKast, Inc. to Globus Medical

Trigon Holding, Inc., a supplier of titanium forgings, machined components and assemblies to the aerospace and medical industries, has sold all the assets of StelKast, Inc. to Globus Medical.

StelKast designs, manufactures and distributes a full line of orthopedic implants for knee and hip replacement systems and surgical instrumentation systems.

Globus Medical is a publicly traded medical device company headquartered in Audubon, Pennsylvania. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Trigon Holdings, Inc. is a supplier of titanium forgings, machined components and assemblies to the aerospace and medical industries.

Oaklins' team in Cleveland acted as the exclusive financial advisor to Trigon Holding, Inc. in this transaction.

DIENSTLEISTUNG
Verkauf
PARTEIEN

Sprechen Sie mit dem Deal Team

 Matthew J. Mueller

Matthew J. Mueller

Managing Director

Cleveland, Vereinigte Staaten
Oaklins Citizens Capital Markets
 Daniel  Fearer

Daniel Fearer

Associate

Cleveland, Vereinigte Staaten
Oaklins Citizens Capital Markets

Transaktionen

Maginnis Orthodontics has been acquired by Smile Doctors
Gesundheitswesen

Maginnis Orthodontics has been acquired by Smile Doctors

Maginnis Orthodontics, Inc. has been sold to Smile Doctors, LLC.

Mehr erfahren
Global Media Santé has been acquired by SFP Expansion
Private Equity | Gesundheitswesen | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Mehr erfahren
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Gesundheitswesen

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Mehr erfahren